United Kingdom· GB-APID-3285511000001103
Human Mixtard 40 Penfill 100units/ml suspension for injection 1.5ml cartridges
A medicinal product containing insulin isophane biphasic human, registered in United Kingdom by Novo Nordisk Ltd.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Insulin isophane biphasic human
- Manufacturer
- Novo Nordisk Ltd
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f9befde0-1229-4e45-8d00-949957689745 GET /v1/drugs/f9befde0-1229-4e45-8d00-949957689745?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "3285511000001103",
"desc": "Human Mixtard 40 Penfill 100units/ml suspension for injection 1.5ml cartridges (Novo Nordisk Ltd)",
"form": "Suspension for injection",
"vpid": "3471111000001104",
"source": "dmd",
"vtm_id": "9820811000001105",
"strength": "40 unit",
"substance": "Insulin isophane biphasic human",
"ingredient": "Insulin soluble human",
"supplier_code": "2080301000001101"
}See everything about insulin isophane biphasic human.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.